HIT is a rare but serious prothrombotic complication associated with UFH and LMWH treatments. Diagnosis of HIT is based on clinical (4T’s score) and laboratory criteria. Nevertheless, over-diagnosis and over-treatment are currently the major problem [1]
- a clinical HIT is confirmed in only [±10%] of patients with a suspicion of HIT [2].
In 90% of patients investigated for HIT, it is important to rule-out HIT early and :
- continue the heparin therapy
- reduce bleeding risks and costs associated with alternative anticoagulants[3]
This is why it is important to have available a test which can be used to detect HIT antibodies. A negative result generally rules out HIT [4]
Asserachrom® HPIA
Two ELISA kits are available:
- 00624 Asserachrom® HPIA-IgG for detection of anti-heparin/PF4 IgG antibodies
- 00615 Asserachrom® HPIA for detection of anti-heparin/PF4 IgA, G and M antibodies
Convenient test format
- microplate format with breakable strips to better suit test series of different sizes
- quality controls and standards included in the kits
Download the brochure
1 - Cuker A; Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis.Thromb Haemost. 2011; 106: 993-994
2 - Warkentin TE. HIT paradigms and paradoxes. Thromb Haemost 2011; 9 (Suppl. 1): 105–117
3 - Gardiner E. et al. DiagnoSTic assays for heparin-induced thrombocytopenia. Br. J.Haematol. 2014, May 12.
4 - Warkentin TE. et al. Laboratory testing for heparin-induced thrombocytopenia : a conceptual framework and implications for diagnosis. J. Thromb. Haemost. 2011; 9 : 2498-500
5 - Leroux D. et al. Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert® HIT) for the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 2014, May 12
6 - Elalamy I. Multicentric evaluation of a new ELISA assay: Asserachrom HPIA-IgG and its potential heparin-induced thrombocytopenia diagnosis. GEHT, 2009, Poster